One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Fluidigm Corporation logo
Fluidigm Corporation FLDM

Fluidigm Corporation Income Statement 2020-2011 | FLDM

Brief overview of profit and loss at Fluidigm Corporation

The conclusions below are based on five years of reported results. Revenue at Fluidigm Corporation moved from $115 million in 2015 to $138 million in 2020. The total change was +20.4%, with a CAGR of approximately 3.8%. Revenue was effectively stagnant over the period.

Gross profit was $68.1 million at the start and $83.3 million at the end of the period (+22.4%). At the margin level, the figure shifted from 59.4% to 60.3%. Gross profitability remained broadly stable.

The five-year EBITDA result moved by +7.7%: from −38 million dollars to −35.1 million dollars. EBITDA lagged revenue, showing weaker operating momentum. EBITDA margin moved from −33.1% to −25.4%. The increased EBITDA share is a positive sign.

Net income moved from −$53.3 million at the start to −$53 million at the end. Losses became smaller, but the business remains unprofitable.

The market value of the business moved from 193 million dollars to 481 million dollars, or +149.8%. Investor expectations increased faster than reported performance.

Overall conclusion

The financial profile remains mixed, with strengths and risks moving in different directions. The positive side is supported by higher operating efficiency, a steady final result and a stable gross margin. The weaker side of the profile includes limited revenue growth and a low EBITDA margin. Investors should continue to monitor margins, costs, and earnings quality.

Annual Income Statement Fluidigm Corporation

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

481 M 262 M 340 M 216 M 175 M 193 M 1.07 B 1.14 B 361 M 264 M

Shares

74.3 M 66.8 M 39.7 M 33 M 29 M 28.7 M 27.8 M 25.5 M 22.1 M 17.8 M

Net Income

-53 M -64.8 M -59 M -60.5 M -76 M -53.3 M -52.8 M -16.5 M -19 M -22.5 M

Revenue

138 M 117 M 113 M 102 M 104 M 115 M 116 M 71.2 M 52.3 M 42.9 M

EBITDA

-35.1 M -36 M -31.6 M -39.8 M -55.3 M -38 M -27.3 M -14.8 M -15.9 M -14.5 M

Operating Expenses

134 M 116 M 110 M 110 M 132 M 122 M 115 M 68.4 M 55.1 M 45.2 M

General and Administrative Expenses

97.9 M 84.5 M 79.8 M 79.5 M 93.2 M 83 M 71.3 M 48.4 M 38.5 M 31.3 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Fluidigm Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Myriad Genetics Myriad Genetics
MYGN
$ 5.54 -0.09 % $ 513 M usaUSA
ENDRA Life Sciences ENDRA Life Sciences
NDRA
$ 4.04 2.93 % $ 5.35 M usaUSA
RadNet RadNet
RDNT
$ 72.01 -3.88 % $ 5.41 B usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
$ 49.57 -0.37 % $ 10.8 B niderlandNiderland
NeoGenomics NeoGenomics
NEO
$ 15.31 0.36 % $ 1.96 B usaUSA
OPKO Health OPKO Health
OPK
$ 1.7 4.63 % $ 1.28 B usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
$ 1.85 1.65 % $ 555 M usaUSA
Neogen Corporation Neogen Corporation
NEOG
$ 11.08 1.61 % $ 2.41 B usaUSA
Personalis Personalis
PSNL
$ 14.97 1.15 % $ 1.34 B usaUSA
Quidel Corporation Quidel Corporation
QDEL
$ 9.62 -2.53 % $ 405 M usaUSA
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Neuronetics Neuronetics
STIM
$ 1.25 -1.95 % $ 82.4 M usaUSA
Trinity Biotech plc Trinity Biotech plc
TRIB
$ 5.83 -3.08 % $ 2.09 B irlandaIrlanda
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
Exagen Exagen
XGN
$ 3.91 3.99 % $ 84.3 M usaUSA
VolitionRx Limited VolitionRx Limited
VNRX
$ 0.18 -4.72 % $ 22.6 M singaporeSingapore
Waters Corporation Waters Corporation
WAT
$ 466.25 3.66 % $ 27.8 B usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
National Research Corporation National Research Corporation
NRC
$ 26.17 1.08 % $ 586 M usaUSA
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
$ 116.3 3.84 % $ 7.28 B usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA
Soleno Therapeutics Soleno Therapeutics
SLNO
- - $ 2.69 B usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Renalytix AI plc Renalytix AI plc
RNLX
- 5.66 % $ 22.7 M britainBritain
DexCom DexCom
DXCM
$ 82.53 0.6 % $ 32.2 B usaUSA
Meridian Bioscience Meridian Bioscience
VIVO
- - $ 1.49 B usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Celcuity Celcuity
CELC
$ 55.51 -3.86 % $ 2.6 B usaUSA
T2 Biosystems T2 Biosystems
TTOO
- -39.35 % $ 313 K usaUSA
Syneos Health Syneos Health
SYNH
- - $ 4.46 B usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Surmodics Surmodics
SRDX
- - $ 608 M usaUSA
Brainsway Ltd. Brainsway Ltd.
BWAY
$ 9.02 -1.04 % $ 306 M israelIsrael
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
Danaher Corporation Danaher Corporation
DHR
$ 228.43 1.18 % $ 163 B usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 2.72 1.87 % $ 88.3 K usaUSA